PARP1 and ovarian carcinoma: Niraparib, a potent and highly selective PARP-1 and PARP-2 inhibitor, is approved by both the United States Food and Drug Administration and the European Medicines Agency for first-line maintenance treatment of adult patients with advanced epithelial ovarian cancer with a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status [9, 10].